Description

(1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-amine hydrochloride is a high-purity chiral cyclopropylamine derivative, specifically designed for pharmaceutical research and development. With a molecular formula of C₉H₁₀ClF₂N and CAS number 1156491-10-9, this compound is widely recognized as a key intermediate in the synthesis of bioactive molecules, particularly in cardiovascular and neurological therapeutics. Its stereochemical purity (1R,2S configuration) ensures optimal reactivity and selectivity in asymmetric synthesis. The hydrochloride salt form enhances stability and solubility, making it ideal for laboratory use. Available in various packaging options, this product meets stringent quality control standards (≥98% purity by HPLC) and is supplied with comprehensive analytical data (MSDS, NMR, HPLC). Suitable for medicinal chemistry, drug discovery, and process optimization.

Properties

• CAS Number: 1156491-10-9
• Complexity: 174
• IUPAC Name: (1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine;hydrochloride
• InChI: InChI=1S/C9H9F2N.ClH/c10-7-2-1-5(3-8(7)11)6-4-9(6)12;/h1-3,6,9H,4,12H2;1H/t6-,9+;/m0./s1
• InChI Key: IMYLOCHFFLYHPS-RDNZEXAOSA-N
• Exact Mass: 205.0469833
• Molecular Formula: C9H10ClF2N
• Molecular Weight: 205.63
• SMILES: C1[C@H]([C@@H]1N)C2=CC(=C(C=C2)F)F.Cl
• Topological: 26
• Monoisotopic Mass: 205.0469833
• Synonyms: 1156491-10-9, (1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-amine;hydrochloride, 829-852-9, (1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine hydrochloride, (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride, 1402222-66-5, Cyclopropanamine, 2-(3,4-difluorophenyl)-, hydrochloride (1:1), (1R,2S)-rel-, (1R TRANS)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPANE AMINE, (1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamine hydrochloride, MFCD16621157, MFCD16875501, (1S,2R)-2-(3,4-Difluorophenyl)-cyclopropanamine Hydrochloride, (1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPAN-1-AMINE HYDROCHLORIDE, WL9Y2C88ZH, SCHEMBL15058586, HY-I0180A, WLZ3550, CS-M1888, CS-M2272, rel-(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride, trans-2-(3,4-Difluorophenyl)cyclopropanamine Hydrochloride, AKOS016004061, EX-7184, FD96534, AC-29734, AS-19951, PD213009, Ticagrelor EP Impurity E (hydrochloride), DB-126228, D97169, EN300-196973, trans-2-(3,4-Difluorophenyl)cyclopropanamine HCl, Z2298098006, (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochlo, (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanaminehydrochloride, 2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride, (1R,2S)-, rac-(1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-amine hydrochloride

This compound serves as a critical building block in the synthesis of ticagrelor and its analogs, acting as a potent P2Y₁₂ receptor antagonist for antiplatelet therapies. It is also utilized in the development of CNS-active agents targeting neurotransmitter modulation. Researchers employ it for in vitro SAR studies due to its rigid cyclopropane scaffold and fluorine-substituted aromatic ring, which influence pharmacokinetic properties. The hydrochloride salt facilitates handling in aqueous reaction systems.

Safety and Hazards

GHS Hazard Statements

• H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
• H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
• H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
• H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]

Precautionary Statements

• P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501

Hazard Classes and Categories

• Acute Tox. 4 (100%)
• Skin Irrit. 2 (100%)
• Eye Irrit. 2 (100%)
• STOT SE 3 (100%)

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.